Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, discusses the current role of molecular biomarkers in assessing a patient’s response to bladder cancer treatment. Furthermore, Dr. Plimack explores the prospective advancements and application of these biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.